Traws Pharma Receives Approval to Proceed with Phase 2 COVID Studies with Ratutrelvir, Expects Results by Year-End 2025
(NASDAQ:TRAW), Non-inferiority trial to assess safety and efficacy, including rates of disease rebound and incidence of Long COVID development of ratutrelvir, a ritonavir-free treatment, compared to PAXLOVID(R) Separate single-arm trial will assess safety and efficacy in PAXLOVID(R)-ineligible subjects, who represent a significant vulnerable population with few available treatment options Top-line data from both trials expected […]